Primary analyses from this phase 3 clinical trial of the investigational, subcutaneous infusion of levodopa/carbidopa (LD/CD) (ND0612) showed that treatment in doses of up to 720 mg/90 mg per day, supplemented with oral levodopa provided almost 2 additional hours per day of “Good On” time without troublesome dyskinesia compared with immediate-release levodopa/carbidopa (IR-LD/CD) at week 12.
Subcutaneous combination therapy improves... - Cure Parkinson's
Subcutaneous combination therapy improves ‘good on’ time in Parkinson’s
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
Written by
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
UC study: Subcutaneous infusion pump safe, effective for Parkinson’s treatment
Levodopa is most commonly administered orally, but this trial tested continuous, 24-hour levodopa...
Light Therapy for Parkinson’s Disease
https://www.apdaparkinson.org/article/light-therapy-for-parkinsons-disease/